Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

@article{Maini1999InfliximabA,
  title={Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial},
  author={R. Maini and E. Clair and F. Breedveld and D. Furst and for the Attract Study Group},
  journal={The Lancet},
  year={1999},
  volume={354},
  pages={1932-1939}
}
  • R. Maini, E. Clair, +2 authors for the Attract Study Group
  • Published 1999
  • Medicine
  • The Lancet
  • BACKGROUND Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate. METHODS In an… CONTINUE READING
    2,355 Citations
    Long term safety of infliximab.
    • T. Schaible
    • Medicine
    • Canadian journal of gastroenterology = Journal canadien de gastroenterologie
    • 2000
    • 109
    • PDF

    References

    SHOWING 1-10 OF 22 REFERENCES